Magnetic Resonance Imaging Techniques in Phase III Clinical Trials in Multiple Sclerosis

  • D. W. Paty
  • D. K. B. Li
Conference paper
Part of the Topics in Neuroscience book series (TOPNEURO)

Abstract

When the lesions of multiple sclerosis (MS) were first seen on magnetic resonance images [1], the possibility for being able to measure those lesions was very exciting [2]. Natural history studies of MS patients using frequent scanning [3–6] revealed that new lesions could be seen to form and previously stable lesions could be seen to enlarge. When gadolinium (Gd) enhancement became available, these morphologically active lesions could be seen to enhance [6]. Based upon this natural history experience the concept of using magnetic resonance imaging (MRI), not only in the diagnosis of MS, but also in monitoring therapeutic trials became possible. The direct measurement of pathological events by MRI as they evolved required a systematic approach to repeated imaging and analysis. As the clinical evaluations in therapeutic trials, acute phase monitoring by frequent scanning could identify new pathological activity (the MRI equivalent to relapses) and chronic phase monitoring could measure the extent of the pathology (roughly equivalent for MRI in concept to the Expanded Disability Status Score (EDSS) [7] as a global scale of neurological impairment) [8]. As more experience accumulated, guidelines were adopted for monitoring therapeutic trials [9, 10] including quantitative measures [11].

Keywords

Multiple Sclerosis Magnetic Resonance Imaging Data Magnetic Resonance Imaging Technique Interferon Beta Magnetic Resonance Imaging Measure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Young IR, Hall AS, Pallis CA, et al. (1981) Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet ii: 1063–1066CrossRefGoogle Scholar
  2. 2.
    Paty DW (1988) Multiple sclerosis: Assessment of disease progression and effects of treatment. Can J Neurol Sci 15: 266–272PubMedGoogle Scholar
  3. 3.
    Isaac C, Li DKB, Genton M, et al. (1988) Multiple sclerosis: A serial study using MRI in relapsing patients. Neurology 38:1511–1515PubMedCrossRefGoogle Scholar
  4. 4.
    Grossman RI, Braffman BH, Brorson JR, et al. (1988) Multiple sclerosis: Serial study of gadolinium-enhanced MR imaging. Radiology 169:117–122PubMedCrossRefGoogle Scholar
  5. 5.
    Willoughby EW, Grochowski E, Li DKB, et al. (1989) Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patient. Ann Neurol 25: 43–49PubMedCrossRefGoogle Scholar
  6. 6.
    Miller DH, Rudge P, Johnson G, et al. (1988) Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111: 927–939PubMedCrossRefGoogle Scholar
  7. 7.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expended disability status scale (EDSS). Neurology 33:1444–1452PubMedCrossRefGoogle Scholar
  8. 8.
    Paty DW, Ebers GB (1998) Multiple sclerosis, vol 40. FA Davis, Philadelphia. (Contemporary neurology series)Google Scholar
  9. 9.
    Miller DH, Albert PS, Barkhof F, et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 39: 6–16PubMedCrossRefGoogle Scholar
  10. 10.
    Miller DH, Barkhof F, Berry I, et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis. Concerted action guidelines. J Neurol Neurosurg Psychiatry 54: 683–688PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Filippi M, Horsfield MA, Adèr HJ, et al. (1998) Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 43: 499–506PubMedCrossRefGoogle Scholar
  12. 12.
    Paty DW, Li DKB, UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized double-blind placebo-controlled trial. Neurology 43: 662–667PubMedCrossRefGoogle Scholar
  13. 13.
    Paty DW (1997) Interferon beta la (Rebif) in the treatment of relapsing-remitting multiple sclerosis: The MRI results of a large multicentre study. Mult Scler 3(5):269Google Scholar
  14. 14.
    Miller DH, et al. (1998) MRI results of the European Betaferon secondary progressive MS trial. Presentation made at the European Neurological Society, 8 June 1998Google Scholar
  15. 15.
    Pozzilli C, Bastianello S, Loudriavtseve T, et al. (1995) Magnetic resonance imaging changes with recombinant human interferon ॆ-la: A short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 61: 251–258CrossRefGoogle Scholar
  16. 16.
    Simon JH, Jacobs LD, Campion M, et al. (1998) Magnetic resonance studies of intramuscular interferon ॆ-la for relapsing multiple sclerosis. Ann Neurol 43: 79–87PubMedCrossRefGoogle Scholar
  17. 17.
    Li DKB, Zhao G, Hyde R, UBC MS/MRI Research Group and PRISMS Study Group (1998) Comparison of the therapeutic effect of interferon beta-1a (Rebif) on different levels of baseline MRI activity. Neurology A190: 50Google Scholar
  18. 18.
    IFNB Study Group, UBC MS/MRI Analysis Group (1995) IFNB beta-lb in the treatment of MS: Final outcome of the randomized controlled trial. Neurology 45: 1277–1285CrossRefGoogle Scholar
  19. 19.
    Kappos L, Patzold U, Dommasch D, et al. (1988) Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis: Results of the German multicenter study. Ann Neurol 23: 56–63PubMedCrossRefGoogle Scholar
  20. 20.
    Kastrukoff LF, Oger JJ, Hashimoto SA, et al. (1990) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 40: 479–486PubMedCrossRefGoogle Scholar
  21. 21.
    Koopmans RA, Li DKB, Redekop WK, et al. (1993) The use of magnetic resonance imaging in monitoring a therapeutic trial with systemic lymphoblastoid interferon therapy of chronic progressive multiple sclerosis. J Neuroimag 3:163–168Google Scholar
  22. 22.
    The Multiple Sclerosis Study Group (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 27: 591–605CrossRefGoogle Scholar
  23. 23.
    Zhao G, Li DKB, Wolinsky JS, et al. (1997) Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. J Neuroimag 7:1–7Google Scholar
  24. 24.
    Jacobs LD, Cookfair DL, Rudick RA, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285–294PubMedCrossRefGoogle Scholar
  25. 25.
    Fischer JS, Priore R, Jacobs L (1998) Neuropsychological effects of Avonex (interferon ॆ-la) in relapsing multiple sclerosis (MS). Neurology A32: 50Google Scholar
  26. 26.
    Ebers GC, Oger J, Paty D, et al. (1998) The multiple sclerosis PRISMS study: Prevention of relapses and disability with interferon ॆ-la subcutaneously in multiple sclerosis. Ann Neurol (in press)Google Scholar
  27. 27.
    Hughes RAC and PRISMS Rebif Study Group (1997) Interferon beta-la (Rebif) in the treatment of relapsing-remitting multiple sclerosis: The clinical results of a large multicentre study. Mult Scler 3(5): 269Google Scholar
  28. 28.
    Johnson KP, Brooks BR, Cohen JA, et al. (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50: 701–708PubMedCrossRefGoogle Scholar
  29. 29.
    Mancardi GL, Sardanelli F, Parodi RC, et al. (1998) Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 50: 1127–1133PubMedCrossRefGoogle Scholar
  30. 30.
    Kappos L, Polman C, Pozzilli C, et al. (1998) Interferon beta-lb (IFN Beta-lb) delays progression of disability in secondary progressive multiple sclerosis: Results of the European Multicentre Study. J Neurol 245:357(abstract)Google Scholar

Copyright information

© Springer-Verlag Italia 1999

Authors and Affiliations

  • D. W. Paty
    • 1
  • D. K. B. Li
    • 2
  1. 1.Division of Neurology, Department of MedicineUniversity of British ColumbiaVancouverCanada
  2. 2.Department of RadiologyVancouver Hospital & Health Sciences CenterVancouverCanada

Personalised recommendations